Recombinant erythropoietin or erythropoietin stimulating agents is synthetic erythropoietin produced by gene cloning. It is given in patients where transfusion is impossible or when the patient is not willing for transfusion. It is provided by an injection that induces the synthesis and release of red blood cells from the bone marrow. Patients under cancer chemotherapy and chronic lung disease patients require it. Increased blood pressure, fever, nausea, pain, and swelling at the injection site are the adverse effects of the drug.
Hi, Welcome back to icliniq.com. So, actually, your hemoglobin level is borderline high and not low. So, you do not have anemia. You are probably thinking about polycythemia.
Hello, Welcome to iciniq.com. The beta thalassemia carrier state, which results from heterozygosity for beta thalassemia, is clinically asymptomatic and is defined by specific hematological features.
Disclaimer: No content published on this website is intended to be a substitute for professional medical diagnosis, advice or treatment by a trained physician. Seek advice from your physician or other qualified healthcare providers with questions you may have regarding your symptoms and medical condition for a complete medical diagnosis. Do not delay or disregard seeking professional medical advice because of something you have read on this website. Read our Editorial Process to know how we create content for health articles and queries.
